title: Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
abstract: OBJECTIVE
  This study investigated the methylation status of the promoter of the tumor suppressor gene cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
  
  
  METHODS
  CDKN2A methylation was quantified by real-time PCR in ovarian biopsies of 52 patients with ovarian cancer, 43 patients with benign ovarian tumors and 40 patients with benign uterine pathology and healthy ovaries.
  
  
  RESULTS
  CDKN2A methylation was detected in the three groups. The methylation level was higher in the cancer patients than in the other two groups (p = 0.0003) but was not different between benign tumors and healthy ovarian tissue (p > 0.05). Using a cutoff threshold based on receiver-operating characteristic analysis, 21 patients with ovarian cancer and three patients with benign tumors were considered positive for CDKN2A methylation while all patients with healthy ovaries were considered negative. At the chosen cutoff, the diagnostic sensitivity was 40.4% and specificity 96.4%. CDKN2A methylation level and frequency were associated with high grade tumors (p = 0.0001 and p = 0.0005) but were not associated with disease stage or serum CA125 levels. However, it should be noted that most patients (92.3%) presented with advanced stage 3 or 4 disease.
  
  
  CONCLUSIONS
  CDKN2A promoter methylation is common in ovarian cancer. Quantification of CDKN2A methylation may be useful in distinguishing malignant from benign ovarian tumors or healthy ovarian tissue.
authors: Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt. aabouzeid4@yahoo.co.uk
authors: Abla A
authors: AA
authors: Abou-Zeid
authors: Amal Z
authors: AZ
authors: Azzam
authors: Nahla A
authors: NA
authors: Kamel
mesh_terms: D000328:Adult; D000368:Aged; D001706:Biopsy; D018394:CA-125 Antigen / Q000032:analysis; D002277:Carcinoma / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D016022:Case-Control Studies; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics / Q000378:metabolism*; D019175:DNA Methylation / Q000235:genetics*; D004534:Egypt; D005260:Female; D006801:Humans; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D010053:Ovary / Q000378:metabolism* / Q000473:pathology; D011230:Precancerous Conditions / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D012372:ROC Curve; D060888:Real-Time Polymerase Chain Reaction; D012680:Sensitivity and Specificity
chemical_list: D018394:CA-125 Antigen; D019941:Cyclin-Dependent Kinase Inhibitor p16